Trovagene Inc. (NASDAQ:TROV) shares saw strong trading volume on Wednesday . 386,357 shares traded hands during mid-day trading, an increase of 27% from the previous session’s volume of 304,625 shares.The stock last traded at $5.01 and had previously closed at $4.84.

Several equities analysts have commented on the stock. Piper Jaffray Cos. reiterated a “hold” rating and issued a $5.00 price objective (down from $8.00) on shares of Trovagene in a report on Thursday, May 12th. Leerink Swann reiterated a “hold” rating on shares of Trovagene in a report on Thursday, May 12th. Argus downgraded shares of Trovagene from a “buy” rating to a “hold” rating in a report on Thursday, April 28th. Zacks Investment Research upgraded shares of Trovagene from a “sell” rating to a “hold” rating in a report on Wednesday, July 13th. Finally, Maxim Group restated a “buy” rating on shares of Trovagene in a research note on Monday, June 6th. Seven research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $6.96.

The firm has a 50 day moving average of $4.76 and a 200-day moving average of $4.77. The stock’s market capitalization is $155.43 million.

Trovagene (NASDAQ:TROV) last issued its quarterly earnings data on Tuesday, May 10th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.29) by $0.07. Equities analysts expect that Trovagene Inc. will post ($1.30) EPS for the current fiscal year.

Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.